The introduction of vancocmycin underscores Alvogen’s focus to deliver to the U.S. market products that fulfill unmet needs for our customers and improve patient care.
Pine Brook, New Jersey (PRWEB) April 10, 2012
Alvogen, Inc. (Alvogen), the U.S.-based generic pharmaceuticals company, today announced the introduction of Vancomycin Hydrochloride Capsules, USP, an antibacterial indicated to treat infections that include C. difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus. The Alvogen product, a generic version of the brand pharmaceutical Vancocin® (vancomycin hydrochloride, USP), is immediately available in 125 mg and 250 mg dosage strengths.
“Alvogen is pleased to launch Vancomycin Hydrochloride as part of our U.S. product portfolio,” stated Doug Drysdale, chief executive officer for Alvogen Americas. “In partnership with Strides Arcolab, Ltd., this introduction of vancocmycin underscores Alvogen’s focus to deliver to the U.S. market products that fulfill unmet needs for our customers and improve patient care.”
Alvogen vancomycin hydrochloride capsules, USP, are immediately available in carton packages that each contains two patient-ready, 10-count unit dose cards.
Alvogen is a multinational pharmaceuticals company focused on complex generic products. Alvogen is committed to build the next-generation generics company through the strategic selection of products, partners and markets, and the utilization of a consolidated global supply chain. The company has more than 200 pharmaceutical products in development, including a broad range of leading molecules in the areas of Oncology, Cardiology, Respiratory, Neurology and Gastroenterology.
Vancocin® is a registered trademark of ViroPharma, Inc.
Alvogen™ is a trademark of Alvogen, Inc.